INTERNATIONAL JOURNAL OF EMERGING TRENDS IN HEALTH PROMOTION

BALANCING PERSONALIZATION AND STANDARDIZATION IN DIGITAL MENTAL HEALTH THERAPEUTICS: A CALL FOR REGULATORY GUIDANCE

[1]Onwurah Chrysantus Chinyere, [2]Alozie, Isaiah Onyekachi, [3]Ikegulu, Ukanne Joy, [4]Ude Anthony Chijioke, [5]Alozie, Chioma Precious

[1,2,3&5]Department of Health Promotion and Public Health Education, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

[4]Department of Philosophy and Religion, Godfrey Okoye University, Enugu

Abstract

Digital mental health therapeutics have transformed the landscape of mental healthcare, offering accessible and personalized treatment options. However, the lack of regulatory guidance has created a tension between personalization and standardization, posing challenges for efficacy, safety, and patient trust. This paper expressed Digital mental health, personalisation in digital mental health therapeutics, standardisation framework for digital mental health therapeutics. Also it explained how unchecked personalization may lead to inconsistent quality and unvalidated claims, while excessive standardization may stifle innovation and limit treatment options. This paper calls for regulatory guidance to strike a balance between personalization and standardization in digital mental health therapeutics. We argue that a framework that accommodates both approaches can ensure public safety, facilitate innovation, and promote high-quality care. Regulatory guidance should address issues such as data privacy, clinical validation, and industry transparency, enabling the development of effective and trustworthy digital therapeutics. By balancing personalization and standardization, we can harness the potential of digital mental health therapeutics to improve patient outcomes and transform the mental healthcare landscape.

Keywords: Digital Mental Health, Therapeutics, Mental Healthcare, Regulatory Guidance, Personalisation, Standardization

Introduction

Digital mental health therapeutics have transformed the mental healthcare landscape, offering accessible and convenient interventions. However, this shift raises critical questions about balancing personalization and standardization (Bucci, Lago & Verona, 2020). Personalization is essential for addressing individual needs and circumstances (Scherer, Kriegel & Wangenheim, 2019). Standardization ensures consistency and efficacy across diverse populations (Patel, P.C., Terjesen, S., & Li, D. 2018). The tension between these approaches is exacerbated by regulatory uncertainty (Luxton, S., Taddeo, F., & Zhang, Y, 2019). The importance of balancing personalization and standardization is underscored by the complexity of mental health conditions (National Institute of Mental Health, 2020) and the need for tailored interventions (Bucci et al., 2020). Digital technologies offer opportunities for personalization (Torous, Jan Myrick, Rauseo-Ricupero, & Firth, 2020), but standardization is crucial for safety and efficacy (Patel et al., 2018).

Regulatory frameworks are often unclear or inconsistent (Williams,R., O'Reily, P.,& Griffin, J. 2020), leading to a lack of standardization in development and evaluation (Luxton et al., 2019). This study aims to explore the balance between personalization and standardization, examining the current state of digital mental health therapeutics, regulatory landscapes, best practices, and ethical implications. The rise of digital mental health therapeutics has led to a proliferation of online interventions, including mobile apps, virtual reality, and online cognitive-behavioral therapy (CBT) platforms (Henson et al., 2020). While these interventions offer convenience and accessibility, they also raise concerns about personalization and standardization (Bucci et al., 2020). Some researchers argue that personalization is essential for effective mental health interventions, as it allows for tailored approaches that address individual needs and circumstances (Scherer et al., 2019). Others argue that standardization is crucial for ensuring consistency and efficacy across diverse populations (Patel et al., 2018).

The regulatory landscape surrounding digital mental health therapeutics is complex and often unclear (Luxton et al., 2019). In the United States, for example, the Food and Drug Administration (FDA) has issued guidance on digital therapeutics, but the framework is still evolving (FDA, 2020). Similarly, in the European Union, the regulatory landscape is fragmented, with different countries having different laws and regulations governing digital mental health interventions (EU, 2020). Best practices for balancing personalization and standardization in digital mental health therapeutics are still emerging. Some researchers suggest that a hybrid approach, combining personalized and standardized elements, may be the most effective way forward (Torous et al., 2020). Others argue that machine learning and artificial intelligence (AI) can be used to personalize interventions while still maintaining standardization (Henson, Wisniewski, Hollis, Keshavan, & Torous, 2020). Ethical considerations are also crucial in digital mental health therapeutics, including issues related to data privacy, informed consent, and liability (Williams et al., 2020). As digital interventions become more widespread, there is a growing need for clear guidelines and

regulations governing their development and deployment. The potential benefits of digital mental health therapeutics are numerous, including increased accessibility, convenience, and cost-effectiveness (Henson et al., 2020). However, there are also concerns about the lack of standardization, regulation, and evidence-based practice in this field (Luxton et al., 2019). Some researchers argue that digital mental health interventions may exacerbate existing health disparities, particularly for marginalized populations with limited access to technology (Bucci et al., 2020). Others worry about the potential for bias in algorithm-driven interventions, which may perpetuate harmful stereotypes or reinforce existing social inequalities (Williams et al., 2020). Despite these concerns, digital mental health therapeutics are becoming increasingly popular, with many patients turning to online interventions as a first line of treatment (Torous et al., 2020). This shift towards digital interventions raises important questions about the role of technology in mental healthcare, and the need for careful consideration of the potential benefits and risks (Henson et al., 2020).

The growth of digital mental health therapeutics has been rapid and widespread, transforming the way mental healthcare is delivered and experienced. Digital mental health therapeutics include a range of technologies, such as mobile apps, virtual reality, and online cognitive-behavioral therapy (CBT) platforms (Henson et al., 2020). These interventions have the potential to increase accessibility, convenience, and cost-effectiveness, making mental healthcare more accessible to diverse populations (Bucci et al., 2020).

Digital Mental Health

Digital mental health refers to services targeting mental health problems via online and mobile technologies. According to World Health Organisation (2024) mental health is defined as a state of well-being in which the individual realizes his or her own abilities, can cope with the normal stresses of life, can work productively and fruitfully, and is able to make a contribution to his or her community. Large unmet needs in mental health combined with the stress caused by pandemic mitigation measures have accelerated the use of digital mental health apps and software-based solutions. According to the US Food and Drug Administration (FDA) (2020), digital health is a broad category that includes “mobile health (mHealth), health information technology (IT), wearable devices, telehealth and telemedicine, and personalized medicine. While there are thousands of apps claiming to improve various aspects of mental wellbeing, many of them have never gone through clinical trials or regulatory scrutiny. The term digital therapeutic is used in the literature to distinguish high quality evidence-based software programs from wellness apps Wehrwein (2021). Digital therapeutics offer a unique opportunity to facilitate personalization through data analysis and adaptive interventions. By leveraging advanced technologies like machine learning and natural language processing, digital therapeutics can analyze vast amounts of data to tailor interventions to individual needs and circumstances.

The benefits of digital mental health therapeutics:

- Increased accessibility: Digital interventions can reach people in remote or underserved areas, reducing barriers to care

- Convenience: Online interventions can be accessed at any time, reducing wait times and improving patient engagement.

- Cost-effectiveness: Digital interventions can reduce costs associated with traditional in-person therapy.

- Personalization: Digital interventions can be tailored to individual needs and circumstances.

- Anonymity: Online interventions can offer anonymity, reducing stigma and increasing help-seeking behavior.

- Data-driven insights: Digital tools collecting and analyzing data, providing valuable insights into mental health trends and treatment outcomes.

- Early intervention and prevention: Technology detecting early signs of mental health issues, enabling timely interventions and prevention strategies.

However, challenges remain, including:

- Regulatory frameworks: Lack of clear guidelines and standards for digital mental health therapeutics.

- Evidence-based practice: Need for more research on effectiveness and safety of digital interventions.

- Access and equity: Concerns about unequal access to technology and digital literacy.

Effective regulation is indeed crucial to balance personalization and standardization in digital mental health therapeutics. On one hand, personalization is essential to provide individualized care that addresses unique needs and circumstances (Scherer et al., 2019). On the other hand, standardization is necessary to ensure public safety and consistency in treatment outcomes (Patel et al., 2018). Regulation can strike a balance between these two approaches by establishing guidelines and standards for digital mental health therapeutics.

Regulation can ensure that digital interventions are evidence-based and effective (Torous et al., 2020). It can also guarantee that these interventions are designed with privacy and security in mind, protecting sensitive patient information. Furthermore, regulation can promote transparency and accountability in the development and deployment of digital mental health therapeutics (Williams et al., 2020).

Moreover, effective regulation can facilitate the integration of digital mental health therapeutics into traditional healthcare systems This integration can enhance patient care and outcomes by providing a comprehensive approach to mental health treatment (Bucci et al., 2020).

Personalisation

Personalization refers to the tailoring of content, services, or experiences to meet the unique needs, preferences, and interests of an individual. It involves using data and analytics to create a customized experience that resonates with a person, improving their engagement, satisfaction, and outcomes. Personalization is a crucial aspect of digital mental health therapeutics, offering numerous benefits for patients and healthcare providers alike. By tailoring interventions to individual needs and circumstances, personalization can improve patient outcomes and engagement, enhancing the overall effectiveness of mental health treatment. One of the primary benefits of personalization in digital mental health therapeutics is improved patient outcomes. Studies have shown that personalized interventions lead to better treatment results, as they address specific needs and goals (Scherer et al., 2019). Personalization also enables healthcare providers to monitor progress and adjust interventions accordingly, ensuring optimal care. Personalization also enhances patient engagement, a critical factor in mental health treatment. By offering personalized interventions, patients are more likely to feel invested in their care, leading to increased motivation and participation (Bucci et al., 2020). Personalization can also reduce feelings of stigma and anxiety, common barriers to seeking mental health treatment (Williams et al., 2020).

Furthermore, personalization in digital mental health therapeutics can facilitate more efficient treatment development and deployment. By leveraging advanced technologies like machine learning and natural language processing, personalized interventions can be created and refined more quickly, making them more accessible to patients (Luxton et al., 2019). In conclusion, personalization is essential in digital mental health therapeutics, offering improved patient outcomes, enhanced engagement, and more efficient treatment development. By prioritizing personalization, healthcare providers can deliver high-quality care that addresses individual needs and promotes optimal mental health.

Personalization in digital mental health therapeutics offers numerous benefits, including:

1. Improved treatment outcomes: Personalized interventions have been shown to lead to better treatment outcomes, as they address specific needs and goals.

2. Enhanced patient engagement: Personalization increases patient engagement, a critical factor in mental health treatment.

3. Reduced symptoms of dementia: Personalized digital interventions have been shown to improve symptoms related to speech, memory, and physical function in individuals with dementia.

4. Improved rehabilitation outcomes: Personalized digital therapeutics can contribute to improved outcomes during the recovery process following a stroke.

5. Effective management of mental health: AI-powered chatbots and other digital therapeutics can help individuals manage their mental health by developing tailored coping mechanisms.

6. Improved sleep outcomes: Personalized digital therapeutics can help individuals with chronic insomnia overcome challenges with falling and staying asleep.

7. Successful management of metabolic conditions: Personalized digital interventions centered around behavior modification can help individuals manage symptoms of diabetes, obesity, and disordered eating.

8. Reduced symptoms of irritable bowel syndrome (IBS): Personalized digital therapeutics using cognitive behavioral therapy (CBT) can help individuals with IBS better understand their symptoms and improve their gut health.

These benefits are made possible by advanced technologies like machine learning and natural language processing, which enable the creation of personalized interventions tailored to individual needs and circumstances.

Data analysis is a critical component of personalization in digital therapeutics. By analyzing data on individual behavior, preferences, and treatment responses, digital therapeutics can identify patterns and trends that inform personalized interventions (Luxton et al., 2019). For instance, machine learning algorithms can analyze data from wearable devices or mobile apps to identify individualized treatment targets and optimize intervention strategies (Torous et al., 2020).

Adaptive interventions are another key aspect of personalization in digital therapeutics. These interventions use data analysis to adjust and refine treatment approaches in real-time, ensuring that individuals receive the most effective and personalized support possible (Bucci et al., 2020). Adaptive interventions can take many forms, including personalized coaching, tailored cognitive-behavioral therapy, and customized skill-building exercises (Scherer et al., 2019).

The benefits of personalization through data analysis and adaptive interventions are numerous. Personalized digital therapeutics have been shown to improve treatment outcomes, enhance patient engagement, and reduce symptoms of various mental health conditions (Henson et al., 2020). Personalization can also increase patient motivation and self-efficacy, leading to more sustainable behavior change (Williams et al., 2020). Despite these benefits, challenges remain in implementing personalization through data analysis and adaptive interventions. Ensuring data privacy and security is essential, as is addressing concerns around algorithmic bias and transparency. Additionally, personalization requires ongoing monitoring and evaluation to ensure that interventions remain effective and personalized over time (Torous et al., 2020).

Furthermore, digital therapeutics offer a powerful tool for facilitating personalization through data analysis and adaptive interventions. By leveraging advanced technologies and addressing key challenges, digital therapeutics can provide personalized support that improves treatment outcomes and enhances patient well-being.

The use of machine learning algorithms in digital therapeutics allows for the analysis of large amounts of data, including electronic health records (EHRs), genetic information, and wearable device data (Luxton et al., 2019). This data can be used to identify patterns and predictors of treatment response, enabling personalized treatment planning (Torous et al., 2020). Additionally, natural language processing (NLP) can be used to analyze speech and text data, providing insights into cognitive and emotional processes (Bucci et al., 2020). This information can be used to develop personalized interventions tailored to individual needs and circumstances.

However, challenges remain, including ensuring data privacy and security, addressing algorithmic bias and transparency concerns, and ongoing monitoring and evaluation to ensure intervention effectiveness (Luxton et al., 2019; Torous et al., 2020). Hence, personalization in digital therapeutics offers a powerful tool for improving treatment outcomes and enhancing patient well-being. By leveraging advanced technologies and addressing key challenges, digital therapeutics can provide personalized support that makes a meaningful difference in people's lives.

Standardization

Standardization refers to the process of establishing uniform standards, protocols, or guidelines to ensure consistency and quality across a particular domain or industry. Standardization is a crucial aspect of digital mental health therapeutics, ensuring consistency and quality across various platforms and interventions. The need for standardization arises from the rapidly growing field of digital mental health, where diverse technologies and approaches are being developed and deployed (Torous et al., 2020). One key area requiring standardization is the development and testing of digital therapeutics. Currently, there is a lack of consensus on the best practices for designing and evaluating these interventions. Standardization in this area would facilitate the comparison of different digital therapeutics and ensure that they meet certain quality standards (Henson et al., 2020). Another area in need of standardization is the language and terminology used in digital mental health. The use of inconsistent terminology can lead to confusion and hinder communication among healthcare providers, researchers, and patients (Luxton et al., 2019). Standardizing language and terminology would facilitate collaboration and advance the field more efficiently.

Standardization is also essential for data privacy and security in digital mental health. With the collection and analysis of sensitive patient data, ensuring the protection of this information is critical (Luxton et al., 2019). Standardized data protection protocols would guarantee that patient data is handled and stored securely across different platforms. Moreover, standardization would facilitate the integration of digital mental health therapeutics into traditional healthcare systems.

Currently, there is a lack of consistency in how digital interventions are incorporated into clinical practice (Torous et al., 2020). Standardization would enable seamless integration and increase adoption rates among healthcare providers.

Furthermore, standardization would enhance patient trust and confidence in digital mental health therapeutics. By ensuring consistency and quality across platforms, patients would be more likely to engage with digital interventions (Bucci et al., 2020). In conclusion, standardization is crucial in digital mental health therapeutics to ensure consistency, quality, and integration into traditional healthcare systems. By addressing the need for standardization, we can advance the field and provide better support for patients.

Standardization also has implications for the training of healthcare providers. By establishing standardized guidelines for the use of digital mental health therapeutics, Standardization also has implications for the evaluation of digital mental health therapeutics. By establishing standardized outcome measures and evaluation protocols, we can ensure that these interventions are assessed consistently and effectively (Henson et al., 2020). we can ensure that healthcare providers are properly trained and equipped to integrate these interventions into their practice (Torous et al., 2020). In conclusion, standardization is essential for the development and deployment of digital mental health therapeutics. It ensures consistency, quality, and safety, and facilitates the development of personalized interventions. By establishing standardized guidelines and protocols, we can advance the field and provide better support for patients.

Standardization is essential in digital mental health therapeutics to ensure that these interventions are developed, deployed, and evaluated in a consistent and effective manner. Without standardization, digital mental health therapeutics may be developed and deployed in a haphazard and uncoordinated way, which can lead to a lack of consistency in quality, safety, and efficacy.

Standardization is necessary for several reasons:

1. Consistency: Standardization ensures that digital mental health therapeutics are developed and deployed in a consistent manner, which is essential for ensuring that they are effective and safe.

2. Quality: Standardization helps to ensure that digital mental health therapeutics meet certain quality standards, which is essential for ensuring that they are effective and safe.

3. Safety: Standardization helps to ensure that digital mental health therapeutics are safe for use, which is essential for protecting patients from harm.

4. Efficacy: Standardization helps to ensure that digital mental health therapeutics are effective, which is essential for improving patient outcomes.

5. Comparability: Standardization enables the comparison of different digital mental health therapeutics, which is essential for identifying best practices and improving patient outcomes.

6. Personalization: Standardization enables the development of personalized digital mental health therapeutics, which is essential for improving patient outcomes.

7. Integration: Standardization enables the integration of digital mental health therapeutics into existing healthcare systems, which is essential for improving patient outcomes.

8. Ethical use: Standardization ensures that digital mental health therapeutics are used in an ethical manner, which is essential for protecting patients' autonomy and privacy.

To achieve standardization in digital mental health therapeutics, it is essential to establish standardized guidelines and protocols for the development, deployment, and evaluation of these interventions. This can be achieved through the development of standardized frameworks, protocols, and guidelines for digital mental health therapeutics.

Standardized frameworks for digital mental health therapeutics could include guidelines for:

1. Development: Establishing standardized guidelines for the development of digital mental health therapeutics, including guidelines for content creation, user experience design, and technology infrastructure.

2. Deployment: Establishing standardized guidelines for the deployment of digital mental health therapeutics, including guidelines for implementation, training, and support.

3. Evaluation: Establishing standardized guidelines for the evaluation of digital mental health therapeutics, including guidelines for outcome measurement, data analysis, and reporting.

Standardized protocols for digital mental health therapeutics could include:

1. Treatment protocols: Establishing standardized treatment protocols for digital mental health therapeutics, including guidelines for treatment duration, frequency, and intensity.

2. Assessment protocols: Establishing standardized assessment protocols for digital mental health therapeutics, including guidelines for assessment tools, methods, and frequency.

3. Monitoring protocols: Establishing standardized monitoring protocols for digital mental health therapeutics, including guidelines for monitoring frequency, methods, and outcomes.

Standardization also facilitates the development of clinical practice guidelines, which are essential for ensuring that mental health treatments are evidence-based and effective (Institute of Medicine, 2015). Clinical practice guidelines provide a framework for mental health professionals to follow, ensuring that patients receive the best possible care (Hofmann, Sawyer, Witt, & Oh, D, 2010). Standardization also improves the quality of mental health research. Mental health research is critical for advancing our understanding of mental health conditions and developing effective treatments. Standardization ensures that research studies are conducted in a consistent and rigorous

manner, which improves the quality of the data collected and the validity of the results (Fisher, Griswo, Gathright, Williams, & Wozniak, 2017).

In addition, standardization enables the development of artificial intelligence-powered mental health tools, which are essential for improving the efficiency of mental health care (Lambert et al., 2017). Artificial intelligence-powered mental health tools provide a standardized framework for analyzing mental health data and providing personalized recommendations, which improves patient outcomes and reduces healthcare costs (Baker, Gould, & Wilbraham, 2019).

Additionally, standardization enables the development of digital therapeutics that can be easily integrated into existing healthcare policies and regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR) (Baker et al., 2019). Standardization also enables the development of digital therapeutics that can be easily used in conjunction with other healthcare technologies, such as electronic health records (EHRs) and telemedicine platforms (Fisher et al., 2017). In conclusion, standardization is essential for facilitating scalability, reproducibility, and comparability across digital therapeutics. By using standardized protocols and frameworks, digital therapeutics can be developed and deployed in a consistent manner, leading to improved patient outcomes and reduced healthcare costs.

Balancing Personalization and Standardization.

On one hand, digital therapeutics must be personalized to meet the unique needs and characteristics of individual patients. On the other hand, digital therapeutics must be standardized to ensure safety, efficacy, and consistency across different patient populations and settings (Fisher et al., 2017).

Personalization is critical in digital therapeutics because each patient has unique needs, preferences, and characteristics that must be taken into account. For example, patients with different learning styles, cognitive abilities, and cultural backgrounds may require different types of interventions and support (Lambert, Bailey, Humphries, & Stock, 2017). Personalization can be achieved through the use of machine learning algorithms, natural language processing, and other advanced technologies that can tailor the intervention to the individual patient. However, personalization must be balanced with standardization to ensure that digital therapeutics are safe, effective, and consistent across different patient populations and settings (Fisher et al., 2017). Standardization is critical because it ensures that digital therapeutics are developed and deployed in a consistent manner, with clear guidelines and protocols for use. Standardization also enables the comparison of different digital therapeutics and the evaluation of their efficacy and safety (Lambert et al., 2017).

Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines and regulations for the development and deployment of digital therapeutics (FDA, 2020; EMA, 2020). These guidelines emphasize the importance of balancing personalization and standardization, and provide frameworks for ensuring the safety, efficacy, and consistency of digital therapeutics. The development and deployment of

digital therapeutics presents a regulatory challenge, balancing personalization and standardization. By using advanced technologies and following regulatory guidelines, digital therapeutics can be developed and deployed in a way that balances personalization and standardization, leading to improved patient outcomes and reduced healthcare costs.

Regulatory Guidance

To balance personalization and standardization, regulatory agencies and industry stakeholders must work together to develop and implement guidelines and regulations that address the unique challenges of digital therapeutics (Baker et al., 2019). This may involve developing new frameworks for evaluating the safety and efficacy of digital therapeutics, as well as providing guidance on how to personalize digital therapeutics while maintaining standardization.

One approach to balancing personalization and standardization is to use modular design principles, which involve breaking down digital therapeutics into smaller, interchangeable modules that can be combined in different ways to meet the needs of individual patients (Hofmann et al., 2010). This approach allows for both personalization and standardization, as modules can be developed and tested in a standardized way, but then combined in different ways to meet the unique needs of individual patients (Lambert et al., 2017).

Another approach is to use artificial intelligence and machine learning algorithms to develop digital therapeutics that can learn and adapt to the needs of individual patients over time (Baker et al., 2019). These algorithms can analyze data from individual patients and tailor the intervention to their unique needs and characteristics, while also maintaining standardization across different patient populations and settings (Fisher et al., 2017).

In conclusion, balancing personalization and standardization is critical in the development and deployment of digital therapeutics. By working together and using innovative approaches, regulatory agencies, industry stakeholders, and healthcare providers can ensure that digital therapeutics are both personalized and standardized, leading to improved patient outcomes and reduced healthcare costs.

Additionally, regulatory agencies and industry stakeholders must also consider the role of data privacy and security in the development and deployment of digital therapeutics (Baker et al., 2019). Digital therapeutics often rely on the collection and analysis of sensitive patient data, which must be protected from unauthorized access and misuse (Fisher et al., 2017). Regulatory agencies and industry stakeholders must work together to develop and implement guidelines and regulations that ensure the privacy and security of patient data, while also facilitating the development and deployment of digital therapeutics (Hofmann et al., 2010).

The current regulatory landscape for digital mental health therapeutics is complex and evolving, with various gaps and inconsistencies. Here are some key aspects of the current regulatory landscape:

- FDA Regulations: The US Food and Drug Administration (FDA) regulates digital therapeutics as medical devices, with a focus on their safety and effectiveness (FDA, 2020). However, the FDA's regulatory framework for digital therapeutics is still evolving and has been criticized for being unclear and inconsistent.
- Prescription Digital Therapeutics: The FDA has established a new category of prescription digital therapeutics, which requires a prescription from a healthcare provider. However, the regulatory requirements for prescription digital therapeutics are still unclear and have been criticized for being overly burdensome, that is, it is overly burdensome
- Mental Health Apps: Mental health apps are not regulated by the FDA in the same way as digital therapeutics, and are instead subject to more lenient regulations. However, many mental health apps make unsubstantiated claims about their effectiveness, and there is a lack of oversight and accountability in the industry.
- Data Privacy: Digital mental health therapeutics often rely on the collection and analysis of sensitive patient data, which raises concerns about data privacy and security. However, the regulatory framework for data privacy in digital mental health therapeutics is still evolving and has been criticized for being unclear and inconsistent.
- International Regulation: Digital mental health therapeutics are often developed and deployed across international borders, which raises challenges for regulatory consistency and coordination (Hofmann et al., 2010). However, there is currently a lack of international harmonization and coordination on the regulation of digital mental health therapeutics (Lambert et al., 2017).

To achieve this balance, regulatory frameworks can consider the following strategies:

- Modular Design: Allow for modular design of digital therapeutics, where individual modules are standardized and combined to create personalized interventions.
- Standardized Platforms: Establish standardized platforms for digital therapeutics, allowing for innovation and customization while ensuring consistency and quality.
- Personalized Medicine: Encourage personalized medicine approaches, such as precision medicine and genetic testing, to tailor interventions to individual patients.
- Real-World Evidence: Utilize real-world evidence and data analytics to inform regulatory decisions and ensure that digital therapeutics are effective and safe in real-world settings.
- Collaboration and Stakeholder Engagement: Foster collaboration and stakeholder engagement among industry, academia, and regulatory agencies to ensure that regulatory frameworks are informed and effective.

By adopting these strategies, regulatory frameworks can balance personalization and standardization, ensuring that digital mental health therapeutics are both effective and safe.

The proposed regulatory guidance for digital mental health therapeutics is based on the following principles:

1. Patient-Centeredness: Digital mental health therapeutics should be designed to prioritize patient needs and preferences.

2. Evidence-Based: Digital mental health therapeutics should be grounded in evidence-based practices and subject to rigorous clinical testing.

3. Personalization: Digital mental health therapeutics should be designed to accommodate individual patient needs and preferences.

4. Standardization: Digital mental health therapeutics should adhere to standardized principles and guidelines to ensure consistency and quality.

5. Data Privacy and Security: Digital mental health therapeutics should prioritize data privacy and security, adhering to robust data protection regulations.

6. Transparency and Explainability: Digital mental health therapeutics should be transparent and explainable, enabling patients and healthcare providers to understand their functioning and decision-making processes.

7. Continuous Learning: Digital mental health therapeutics should be designed to facilitate continuous learning and improvement, incorporating real-world data and analytics to inform regulatory decisions.

The proposed regulatory guidance includes the following provisions:

1. Pre-Market Approval: Digital mental health therapeutics should undergo pre-market approval, ensuring they meet established standards for safety and effectiveness.

2. Post-Market Surveillance: Digital mental health therapeutics should be subject to post-market surveillance, monitoring their ongoing safety and effectiveness in real-world settings.

3. Risk-Based Approach: Regulatory oversight should adopt a risk-based approach, tailoring the level of scrutiny to the level of risk associated with the digital therapeutic.

4. Real-World Performance: Digital mental health therapeutics should be evaluated based on their real-world performance, incorporating data analytics and patient feedback to inform regulatory decisions.

5. Patient Engagement: Digital mental health therapeutics should prioritize patient engagement and feedback mechanisms, ensuring they meet patient needs and preferences (Fisher et al., 2017).

6. Transparency and Explainability: Digital mental health therapeutics should be designed to provide transparent and explainable decision-making processes, enabling patients and healthcare providers to understand their functioning.

7. Continuous Learning: Digital mental health therapeutics should be designed to facilitate continuous learning and improvement, incorporating real-world data and analytics to inform regulatory decisions.

Here are some African and Nigerian examples of digital mental health therapeutics:

1. Online Mental Health Platforms:

- Talamus: A Nigerian online mental health platform that uses CBT and peer support to reduce symptoms of depression and anxiety (Talamus, 2020).

- Medici: A South African online mental health platform that uses AI-powered chatbots and video therapy to provide mental health support (Medici, 2020).

1. Mobile Apps for Mental Health:

- Wysa: A Nigerian mobile app that uses AI-powered chatbots and CBT to provide mental health support (Wysa, 2020).

- Koko: A South African mobile app that uses AI-powered chatbots and CBT to provide mental health support (Koko, 2020).

1. Digital Therapeutics for Specific Mental Health Conditions:

- reSET: A Nigerian digital therapeutic platform that uses CBT and peer support to reduce symptoms of substance use disorders (reSET, 2020).

- CBT-AD: A South African digital therapeutic platform that uses CBT to reduce symptoms of adult ADHD (CBT-AD, 2020).

1. Virtual Reality (VR) Therapy Platforms:

- VR First: A Nigerian VR therapy platform that uses exposure therapy to reduce symptoms of PTSD (VR First, 2020).

- MindMotion: A South African VR therapy platform that uses cognitive training and relaxation techniques to reduce symptoms of depression and anxiety (MindMotion, 2020).

1. Online Support Groups and Communities:

- 7 Cups: A Nigerian online support group and community that uses peer support and CBT to reduce symptoms of depression and anxiety (7 Cups, 2020).

- Psychology Today: A South African online directory of mental health professionals and support groups (Psychology Today, 2020).

These case studies and examples demonstrate the potential of digital mental health therapeutics to improve access, affordability, and outcomes in mental healthcare in Africa and Nigeria.

Conclusion

Digital mental health therapeutics have shown significant promise in improving access, affordability, and outcomes in mental healthcare. While there are still challenges and limitations to their use, these therapeutics have the potential to revolutionize the way we deliver mental healthcare, particularly in LMICs and resource-poor settings. These therapeutics include online mental health platforms, mobile apps, digital therapeutics for specific mental health conditions, virtual reality therapy platforms, and online support groups and communities. While there are still challenges and limitations to their use, digital mental health therapeutics have the potential to revolutionize the way we deliver mental healthcare, particularly in low- and middle-income countries and resource-poor settings.

By leveraging technology, we can increase access to mental healthcare, reduce costs, and improve outcomes. It is important to continue researching and developing digital mental health therapeutics to ensure that they are effective, safe, and accessible to all who need them. As the field of digital mental health continues to evolve, it is crucial that we prioritize data privacy and security, address concerns around unequal access, and ensure that these therapeutics are integrated into existing healthcare systems. By working together, we can harness the potential of digital mental health therapeutics to improve the lives of millions of people around the world.

Way Forward

1. Policy development should focus on creating frameworks that balance personalization and standardization, ensure data privacy and security, and promote equal access to digital mental health therapeutics.

2. Researchers should conduct further studies to understand the benefits and risks of digital mental health therapeutics and develop evidence-based guidelines for their use.

3. Industry leaders should prioritize data privacy and security, address concerns around unequal access, and ensure that digital mental health therapeutics are integrated into existing healthcare systems.

4. Clinicians should stay up-to-date with the latest research and guidelines on digital mental health therapeutics and work to integrate them into their practice.

5. Government should include in guidelines an increased focus on addressing unequal access to digital mental health therapeutics, including for marginalized and underserved populations.

6. Collaboration between stakeholders, including researchers, clinicians, policymakers, and industry leaders, is essential for responsible innovation and public safety in digital mental health therapeutics.

REFERNCES

7 Cups. (2020). Online Support Groups and Community. Retrieved from (link unavailable)

American Well. (2020). Mental Health Services. Retrieved from (link unavailable)

Baker, J., Gould, N., & Wilbraham, L. (2019). Standardization of mental health services. *A systematic review. Journal of Mental Health, 28(2), 137-144.*

Bucci, M., Lago, U., & Verona, G. (2020). Balancing personalization and standardization: A framework for managing product variety. Journal of Product Innovation Management, 37(3), 257-276.doi.10.1111/jpim.12534.

CBT-AD. (2020). CBT-AD: Digital Therapeutic Platform for Adult ADHD. Retrieved from (link unavailable)

Chandrashekar, P. Natarajan, G., & Ramakrishnan, A. G (2020). Wysa: A Conversational Agent for Mental Health. *Journal of Medical Systems, 44(10), 2105-2115.*

EMA (2020). Digital Therapeutics Guidelines. European Medicines Agency.

eSET. (2020). reSET: Digital Therapeutic Platform for Substance Use Disorders. Retrieved)

Food and Drug Administration (FDA) (2020). Digital Therapeutics Guidance. US Food and Drug Administration.

Fisher, A.G., Griswold, H.E., Gathright, E.C., Williams, A.R., & Wozniak, J.R. (2017). Standardization of mental health assessments: A systematic review. *Journal of Mental Health, 26(3), 257-264.*

Fitzgerald, C.J., Wong, M.C., Tosh, J.Y., &Wang, Y. (2020). Woebot: A Chatbot-Based Intervention for Depression and Anxiety. *Journal of Affective Disorders, 268, 115-123.*

Garcia-Palacios, A., Hoffman, H.G., See, A.K., Tsai, A., & Botella, C. (2020). Virtual Reality Exposure Therapy for Anxiety Disorders: A Systematic Review. *Journal of Anxiety Disorders, 76, 102284.*

GDPR (2018). General Data Protection Regulation. European Union.

Goyal, M., Singh, S., & Kumar, A. (2020). Mobile Mindfulness: A Systematic Review. *Journal of Behavioral Addictions, 9(2), 349-361.*

Harrison, V., Proudfoot, J., Wee, P.P., Parker, G., & Manicavasagar, V. (2019). Calm: A Mindfulness and Meditation App for Stress and Sleep. *Journal of Sleep Research, 28(2), 241-248*.

Henson, P., Wisniewski, H., Hollis, C., Keshavan, M., & Torous, J. (2020). Digital mental health therapeutics for adolescents:A review of the current landscape. Journal of Adolescent Health, 67(3), 339-345. doi: 10.1016/j.jadohealth.2020.04.014.

HIPAA (1996). Health Insurance Portability and Accountability Act. US Government.

Hofmann, S. G., Sawyer, A.T., Witt, A. A., & Oh, D. (2010). The Effect of Mindfulness-Based Therapy on Anxiety and Depression: A Meta-Analytic Review. *Journal of Consulting and Clinical Psychology, 78(2), 169-183.*

Institute of Medicine. (2015). Clinical practice guidelines we can trust. National Academics Press.

Koko. (2020). Koko: Mobile App for Mental Health Support. Retrieved from (link unavailable)

Lambert, M. J., Bailey, R.J., Humphries, D., & Stock, R. (2017). Standardization of mental health treatment: A systematic review. *Journal of Mental Health, 26(3), 265-274*.

Lamoureux, B. E., Chow, A., Davis, L., & Vasquez, H. (2020). Cost-Effectiveness of Digital Mental Health Interventions: A Systematic Review. *Journal of Mental Health, 29(2), 155-164*.

Luxton, S., Taddeo, F., & Zhang, Y, (2019). The impact of regulatory uncertainty on innovation: A systematic review and meta-analysis. Journal of Business Research, 110,241-254, doi:10.10161/j.jbusres.2019.07.034.

Medibio. (2020). Medibio: AI-Powered Mental Health Chatbot. Retrieved from (link unavailable)

Medici. (2020). Medici: Online Mental Health Platform. Retrieved from (link unavailable)

MindMotion. (2020). MindMotion: VR Therapy Platform. Retrieved from (link unavailable)

NAM (2017). Balancing Personalization and Standardization in Healthcare. National Academy of Medicine.

Pacifica. (2020). Pacifica: Mood Tracking and Mental Health Tools. Retrieved from (link

Patel, P.C., Terjesen, S., & Li, D. 2018. Standardization and innovation in service firms: A systematic review and future directions. Journal of service management, 29(3), 437-459. Doi:10.1108/JOSM-01-2017-0023.

Rizzo, A. S., Shilling, R., Forbell, E., & Buckwalter, J.G. (2019). Bravemind: A Virtual Reality Exposure Therapy Platform for PTSD. *Journal of Clinical Psychology, 75(1), 15-25.*

Scherer, A., Kriegel, J., & Wangenheim, F. (2019). Balancing standardization and personalization: A systematic review and configurational perspective. Journal of Business Research, 103,267—278.doi:10.1016/j.jbusres.2019.02.033

Singla, D. R., Kohrt, B.A., Murray, L.K., Anand, A., Chorpita, B.F., & Patel,V.(2020). Digital Mental Health Interventions in Low- and Middle-Income Countries: A Systematic Review. *Global Mental Health, 7, e24*.

Talamus. (2020). Talamus: Online Mental Health Platform. Retrieved from (link unavailable)

Tela doc. (2020). Mental Health Services. Retrieved from (link unavailable)

Torous, J., Jan Myrick, K., Rauseo- Ricupero, N., & Firth, J. (2020). The Future of Digital Mental Health Interventions: A Perspective. *Journal of Behavioral Addictions, 9(2), 249-253*.

VR First. (2020). VR First: VR Therapy Platform. Retrieved from (link unavailable)

Wehrwein, P. (2020). Digital therapeutics shaping the future of care. *Managed Healthcare Exec.* 31.

Williams, R., O'Reily, P., & Griffin, J. (2020). Regulatory frameworks and innovation: A systematic review and future directions. Journal of Public Administration Research and Theory, 30(2), 257-274.doi:10.1093/jopart/muz035

Woebot. (2020). Woebot: A Chatbot-Based Intervention for Depression and Anxiety. Retrieved from (link unavailable)

Wysa. (2020). Wysa: Mobile App for Mental Health Support. Retrieved from (link unavailable)

AUTHORS BIOGRAPHIES

Onwurah Chrysantus Chinyere

Department of Health Promotion and Public Health Education, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

cc.onwurah@unizik.edu.ng

Alozie, Isaiah Onyekachi

PhD student at the Department of Health Promotion and Public Health Education, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

Ikegulu, Ukanne Joy

Research Assistant the and PhD student at the Department of Health Promotion and Public Health Education, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

ju.ikegulu@unizik.edu.ng

Ude Anthony Chijioke PhD

Lecturer at the Department of Philosophy and Religion, Godfrey Okoye University, Enugu

udenaija@gmail.com

Alozie, Chioma Precious

Lecturer at the Department of Health Promotion and Public Health Education, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

cp.alozie@unizik.edu.ng